Bleeding and thrombosis risk matters: how long can we stick to the one-size-fits-all strategy of platelet inhibition?

JACC Cardiovasc Interv. 2013 Aug;6(8):864-6. doi: 10.1016/j.jcin.2013.06.002.
No abstract available

Keywords: bleeding; clopidogrel; percutaneous coronary intervention; prasugrel; stent thrombosis; therapeutic window.

Publication types

  • Editorial
  • Comment

MeSH terms

  • Acute Coronary Syndrome / therapy*
  • Clopidogrel
  • Female
  • Hemorrhage / chemically induced*
  • Humans
  • Male
  • Percutaneous Coronary Intervention*
  • Piperazines / adverse effects*
  • Platelet Activation / drug effects*
  • Platelet Aggregation Inhibitors / adverse effects*
  • Prasugrel Hydrochloride
  • Thiophenes / adverse effects*
  • Ticlopidine / adverse effects
  • Ticlopidine / analogs & derivatives*

Substances

  • Piperazines
  • Platelet Aggregation Inhibitors
  • Thiophenes
  • Clopidogrel
  • Prasugrel Hydrochloride
  • Ticlopidine